

H1000 Lot No. 2310283

Human Liver Microsomes

Male, Pool of 10

0.5 mL at 20 mg protein / mL

Suspension medium: 250 mM sucrose

Specific Content and Enzyme Activities			Content / Rate
Cytochrome P450 content	(nmol/mg protein)		0.478
Cytochrome b ₅ content	(nmol/mg protein)		0.429
NADPH-cytochrome c reductase	(nmol/mg protein/min)		203 ± 2
Glucuronidation of 4-Methylumbelliferone	(nmol/mg protein/min)		120 ± 15

Enzyme	Marker Substrate Reaction	[S] (μM)	Rate (pmol/mg protein/min)
CYP1A2	Phenacetin O-dealkylation	80	543 ± 28
CYP2A6	Coumarin 7-hydroxylation	50	1060 ± 50
CYP2B6	Bupropion hydroxylation	500	459 ± 41
CYP2C8	Amodiaquine N-dealkylation	20	2280 ± 90
CYP2C9	Diclofenac 4'-hydroxylation	100	3280 ± 180
CYP2C19	S-Mephenytoin 4'-hydroxylation	400	56.5 ± 5.2
CYP2D6	Dextromethorphan O-demethylation	80	195 ± 8
CYP2E1	Chlorzoxazone 6-hydroxylation	500	2340 ± 210
CYP3A4/5	Testosterone 6β-hydroxylation	250	2710 ± 130
CYP3A4/5	Midazolam 1'-hydroxylation	30	856 ± 25
CYP4A11	Lauric acid 12-hydroxylation	100	2400 ± 30

Characterization is performed when the first lot of a product from a given subcellular fraction (e.g., S9) is prepared. Subsequent lots are subject to a verification test only. Values for enzyme activities were determined at a single substrate concentration and are mean ± standard deviation of three or more determinations.

To measure cytochrome P450 (CYP) activity, liver microsomes (50 μg/mL) were incubated in triplicate at 37 ± 2°C for 10 minutes in potassium phosphate buffer (50 mM, pH 7.4), containing MgCl₂ (3.0 mM), EDTA (1.0 mM), NADP (1.0 mM), glucose-6-phosphate (5.0 mM), glucose-6-phosphate dehydrogenase (1 Unit/mL) and marker substrate, at the final concentrations indicated. Metabolite formation was determined by validated LC-MS/MS methods with deuterated metabolites as internal standards. FMO activity was measured under similar conditions except the protein concentration was 1 mg/mL and the buffer was 49 mM Tricine (pH 8.5).

To measure UDP-glucuronosyltransferase (UGT) activity, liver microsomes (10 - 250 μg/mL) were incubated in triplicate at 37 ± 2°C for 5 or 10 minutes in Tris-HCl (100 mM, pH 7.7 at 37°C), CHAPS (0.5 mM), EDTA (1.0 mM), MgCl₂ (10 mM), D-saccharic acid 1,4-lactone (100 μM), uridine diphosphate-glucuronic acid (8.0 mM) and marker substrate at the final concentrations indicated.



Store at -80°C

CAUTION: This sample should be considered as a potential biohazard and universal precautions should be followed. Intended for *in vitro* use only.

These data were generated by and are the property of XenoTech. These data are not to be reproduced, published or distributed without the express written consent of XenoTech.

This data sheet serves as a Certificate of Analysis and has been approved by **Stephanie Helmstetter, Assistant Director.**
 Signature and Date: Stephanie Helmstetter 30 October 2023

Donor Information

Sample	Gender	Age (Yrs)	Race	Cause of Death
468	M	47	Caucasian	Cerebrovascular accident
479	M	65	Caucasian	Anoxia
533	M	28	African American	Anoxia
549	M	55	Caucasian	Cerebrovascular accident
551	M	2	Caucasian	Head Trauma
772	M	46	Caucasian	Anoxia
790	M	52	Caucasian	Cerebrovascular accident
803	M	23	African American	Head Trauma
812	M	73	Caucasian	Cerebrovascular accident
1007	M	20	Caucasian	Head Trauma

Serology information

- Cytomegalovirus: 8 donors tested positive.
- RPR*: All donors tested negative
- HIV, HTLV, HbsAg, and HCV**: All donors tested negative.

* Rapid Plasma Reagin

** Antibody to Human Immunodeficiency Virus, Antibody to Human T Cell Lymphotropic Virus, Hepatitis B Surface Antigen, Antibody to Hepatitis C Virus, respectively.

These data were generated by and are the property of XenoTech. These data are not to be reproduced, published or distributed without the express written consent of XenoTech.